

**Department of Radiation Oncology**  
**University of Maryland School of Medicine/Medical Center**  
**ASTRO Abstracts Submitted 2014**  
**Total Submitted: 28**  
**Total Accepted: 26**

1. Bhooshan N, Sharma NK, Moeslein FM, Horiba M, Hanna NN, Alexander H, Hausner PF, Regine WF, Amin PP, Kudryasheva S, Chuong MD. Pre-treatment tumor volume as a prognostic factor in metastatic colorectal cancer patients who received selective internal radiation therapy to the liver using yttrium-90 coated resin microspheres. ACCEPTED, POSTER
2. Boggs DH, Hanna A, Horiba N, Burrows S, Suntharalingam M. Primary gross tumor volume is an important prognostic factor in locally advanced esophageal cancer patients treated with trimodality therapy. ACCEPTED, POSTER
3. Choi E, Diamond A, Hanna AD, Boggs H, Kwok Y, Feigenberg S, Simard M, Barnholtz-Sloan J, Mehta M. Application of a survival-predicting nomogram based primarily on whole brain radiotherapy treated patients with brain metastases yields significant underestimates for radiosurgery treated patients. ACCEPTED, POSTER
4. Chuong MD, Bhooshan N, Moeslein FM, Horiba M, Hanna NN, Alexander H, Hausner PF, Regine WF, Amin PP, Kudryasheva S, Sharma NK. Radiographic tumor volume change as a prognostic factor for overall survival in metastatic colorectal cancer patients who received selective internal radiation therapy to the liver using yttrium-90 resin microspheres. ACCEPTED, POSTER
5. Chuong MD, Bhooshan N, Sharma NK, Moeslein FM, Horiba M, Hanna NN, Alexander H, Hausner PF, Regine WF, Amin PP, Kudryasheva S, Yi B. Radiation dose versus activity as a prognostic factor in metastatic colorectal cancer patients who received selective internal radiation therapy to the liver using yttrium-90 SIR-spheres microspheres. ACCEPTED, POSTER
6. Cohen RJ, Xue M, Chung H, Feigenberg SJ, Lu W. Pre-treatment SBRT imaging correlates equally well with multi-phase 4DCT and averaging of 4DCT simulation. ACCEPTED, POSTER
7. Den RB, Karnes RJ, Feng FY, Showalter TN, Mishra N, Trabulsi EJ, Lallas CD, Gomella LG, Birbe R, McCue P, Yousefi K, Ghadessi M, Davicioni E, Knudsen KE, Dicker AP. Validation of a genomic classifier for predicting metastasis following post-operative radiation therapy in high-risk prostate cancer. ACCEPTED, ORAL
8. Engelman A, Kumar S, Hussain A, Riedel D, Kwok Y. The efficacy and toxicity outcomes of HIV-infected patients with prostate cancer treated with definitive radiation therapy. ACCEPTED, POSTER
9. Gondi V, Tome W, Mehta MP. Real-time pre-treatment review limits unacceptable deviations: quality assurance (QA) results of RTOG 0933. ACCEPTED, POSTER
10. Hanna A, Boggs D, Kwok Y, Eisenberg H, Simard M, Woodworth G, Regine W, Mehta M. Factors predicting for increase in peritumoral edema following radiosurgery for brain metastases. ACCEPTED, POSTER

11. Kwok Y, Snider JW, Engelman A, Alexander R, Amin P, Hussain A. Long-term follow-up of a prospective trial of neoadjuvant chemotherapy and androgen deprivation followed by prostatectomy and adjuvant radiation in high risk prostate cancer. ACCEPTED, POSTER
12. Lin J, Mehta M, Cohen R, Sharma N, Nichols E, Feigenberg S. Large tumor size increases the risk of developing symptomatic pleural effusions following stereotactic body radiation therapy for lung cancer. ACCEPTED, POSTER
13. Lin MH, Lin J, Langen K, Feigenberg S, Mehta M. The feasibility of breath-hold IMPT for different energy switching time/spot delivery time. ACCEPTED, ORAL
14. Mehta MP, Pugh S, Shaw EG, Buckner J, Gilbert M, Barger G, Coons S, Ricci PP, Bullard D, Curran WJ. Mature survival outcomes data from RTOG 9802: a phase III Study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) for adult patients with high-risk low-grade glioma (LGG) ACCEPTED, ORAL
15. Meister M, Rutenberg M, Amin P, Hussain A, Naslund MJ, Kwok Y. Clinical experience of full-dose external beam radiation in prostate cancer patients failing initial treatment with prostate brachytherapy. ACCEPTED, POSTER
16. Mishra MV, Louie AV, Gondi V, Mehta MP. Is prophylactic cranial irradiation (PCI) with hippocampal avoidance (HA) justified in limited stage small cell lung cancer (LS-SCLC)? ACCEPTED, POSTER
17. Mooney K, Chen S, Feigenberg SJ, Sharma N, D'Souza WD. Determining the internal margin (IM) for lung and gastrointestinal tumors based on real-time measurements. ACCEPTED, POSTER
18. Nichols EM, Kesmodel S, Drogula C, Citron W, Cohen R, Morgan M, Vadnais P, Hall A, Tkaczuk K, Regine WF, Feigenberg SJ. Prospective evaluation of preoperative 3D conformal accelerated partial breast irradiation (3DCRT-APBI) shows promising early results. ACCEPTED, POSTER
19. Patel K, Feigenberg S, Kligerman S, Chuong M, Nichols L, Spaeth K, Hanlon, A, Mehta M. Comparison of coronary vessel contouring using non-contrast cardiac gated CT vs. CT angiogram. ACCEPTED, POSTER
20. Polf J, Beddar S, Mackin D. Verifying proton treatment delivery using prompt gamma imaging. ACCEPTED, POSTER
21. Rockne RC, Bacchus I, Bridge C, Brown PD, Corwin D, Desai B, Hendrickson K, Kim M, Kokkinos E, Mehta MP, Marymont M, Rockhill JK, Rosenberg A, Trister AD, Williams CK, Williamson R, Young L, Swanson KR. An evaluation of multi-institutional data-transfer to facilitate personalized computational modeling. ACCEPTED, POSTER
22. Rutenberg MS, Schinkel C, Yang X, Amin P, Vujaskovic Z, Prado K, Yi B. Dosimetric advantages of an adaptive strategy using dual-plan superposition for whole pelvis radiotherapy in high risk prostate cancer. ACCEPTED, POSTER
23. Shi X, D'Souza WD, Mistry N. MRI based lung perfusion as a tool to evaluate lung function in patients undergoing radiotherapy for pulmonary neoplasms. ACCEPTED, POSTER

24. Snider JW III, Francis M, Hanna N, Alexander H, Sausville E, Amin PP, Regine WF. Use of “virtual” high dose rate (HDR) brachytherapy via spatially fractionated GRID radiation therapy (SFGRT) as part of neoadjuvant therapy in poor prognosis, bulky sarcomas. ACCEPTED, POSTER
25. Snider JW III, Mutaf Y, Feigenberg SJ, Hall A, Vadnais P, Regine WF, Nichols EM. Theoretical improvements in cosmetic outcomes utilizing a novel breast stereotactic radiotherapy (BSRT) device compared to 3-dimensional partial breast irradiation using IMRT (IMRT PBI): a dosimetric analysis. ACCEPTED, POSTER
26. Snider JW III, Nichols EM, Feigenberg SJ, Hall A, Vadnais P, Regine WF, Mutaf YD. A dosimetric comparison of a novel breast stereotactic radiotherapy (BSRT) device for the delivery of partial breast irradiation (PBI) versus intensity modulated radiotherapy (IMRT) PBI. ACCEPTED, ORAL
27. Yi B, D’Souza W, Prado KL. Determination of risk-based target margins: a failure mode and effect analysis (FMEA) proof of principle. ACCEPTED, POSTER